Ethyl 8-bromooctanoate (CAS NO : 29823-21-0)

Ethyl 8-bromooctanoate (CAS No: 29823-21-0) serves as a sophisticated bifunctional building block in the high-growth pharmaceutical synthesis sector, where its terminal bromine and ester moieties enable critical carbon-chain elongation and nucleophilic substitution reactions for producing anesthetics, anticonvulsants, and antihistamines. The global market for this brominated intermediate is projected to reach $94.8 million by 2034, driven by a 4.8% CAGR and a dominant 42.5% application share in pharmaceutical manufacturing, particularly as American CDMOs increasingly prioritize high-purity grades exceeding 98% to meet stringent regulatory standards. Furthermore, the compound is emerging as a vital precursor in agrochemical innovation for the synthesis of advanced herbicides and fungicides, while also finding niche utility in medicinal chemistry as a targeted inhibitor of the NF-κB signaling pathway by binding to BET family bromodomains. As an established Ethyl 8-bromooctanoate supplier in the United States with >98.0% purity, we ensure dependable supply, consistent quality, and complete regulatory documentation, including CoA and TDS across all grades. Beyond supply, we support partners through the entire product lifecycle from route scouting, process and formulation development, and analytical method development to scale-up, process optimization, and pilot-to-commercial manufacturing. Our teams also assist with GMP-compliant quality assurance, regulatory documentation, and global supply chain and logistics coordination.